- About Us
-
Our Business
-
- Therapeutic Areas Our portfolio is diverse and based upon - Market Research, Regulatory & IP.
- Licensing Licensing activities are excellent opportunities for companies to expand their portfolio.
- Biosimilar Biosimilar are biologic medicines that are developed to match their reference medicine.
-
- CRAM India has grown to be one of the key nations complying GMP manufacturing norms.
- Medical Devices REVA help our clients to deliver customized, cost-effective medical device value chain.
-
API
-
Dosage form
-
-
Operations
- At Reva, we have requisite infrastructure, with a balanced reach across Regulated, Emerging & Expansion markets. And we are committed to helping create healthier communities worldwide through education, outreach and better access to treatment.
-
Research & Development
-
Manufacturing
-
Quality
- Media
- Contact us
Participation at JAPAN CPhI (2016) | 20 April, 2016
CPhI Japan, which was held during April 20–22, 2016, at the Big Sight Exhibition Centre, Tokyo, marks its 15th year with exhibits and conferences that examine the current and evolving state of the world’s second largest pharmaceutical market. Over 16,000 pharma professionals gathered for a host of events that covered all aspects of the pharmaceutical supply chain.
It was Reva Pharma's 2nd year of Participtaion as an Exhibitor. The Company is commiited to build its vision of Contract Manufacturing. Reva Pharma stands aligned with the government’s decision to raise the target for generic use from 60% by the end of April 2018 to 80% by April 2021.
Dr. Gurpreet Sandhu’s subject during his seminar was “Mergers & Acquisitions – ‘Growth Strategy’ for Innovator Companies & Generic Industry†which was held on the first day.